NEW YORK (GenomeWeb News) – Danish firm Nuevolution and drugmaker GlaxoSmithKline have inked a cross-licensing agreement covering DNA-tagging, synthesis, and small molecule compounds, Nuevolution said today.

Under the agreement, GSK will obtain a non-exclusive license for Nuevolution's technology, and Nuevolution will obtain a one-time license fee and a non-exclusive license under GSK's patents.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.